Top Penny Stock #1: Marshall Edwards, Inc. (NASDAQ:MSHL)
Share price as of 10/07/2009: $0.75
Market Cap as of 10/07/2009: $55.10 million
http://marshalledwardsinc.com
Biotech Marshall Edwards Inc. (MEI) is a fully owned subsidiary of the Australian company Novogen Ltd.
The company was formed to develop cancer therapies based on a new family of chemicals known as multiple signal transduction regulators.
Phenoxodiol
MEI’s top candidate based on this technology is phenoxodiol. It inhibits anti-apoptotic proteins triggering a reaction that causes cancer cell death.
The drug is currently in a multi-national Phase III trial call OVATURE (for ovarian tumor response). They are testing the effectiveness for women suffering from recurrent ovarian cancer taking the drug orally in combination with carboplatin. Preliminary results are expected by mid-2011.
Each year, approximately 140,000 deaths worldwide are attributed to ovarian cancer.
The drug is also in a PhaseI1/IIa trial to see its safety, tolerability and efficacy in combination with docetaxol versus docetaxol alone in patients with recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer.
For the treatment of castrate and non-castrate prostate cancer, the drug is in a Phase II trial.
NV-128
Recently, MEI signed a licensing agreement with Novogen to take charge of oncology compound NV-128.
In pre-clinical studies, NV-128 promoted cell death in cancers that had proven resistant to other drug therapies. It does this by inhibiting the mTOR pathway that appears to transmit the signals that enhance tumor growth.
The 52-week high for MEI’s share price was $3.31.
This stock could prove a big winner in the long-term… and you can’t beat the price.
I recommend you purchase shares of Marshall Edwards, Inc. (NASDAQ:MSHL) under $0.90.
Top Penny Stock #2: Green Technology: ZAP (OTC:ZAAP)
Share price as of 10/07/2009: $0.30
Market Cap as of 10/07/2009: $30.80 million
http://www.zapworld.com/
Green technology company ZAP manufactures electric vehicles. All kinds of electric vehicles: trucks, vans, scooters, ATVs and, of course, cars.
The ZAP website is a fun read (they call their ATV the ZAP Dude). You can apparently even order a vehicle via their shopping cart function. Check it out here: http://www.zapworld.com/
My favorite is their Vespa-modeled electronic scooter called Zapino. (Though I note it costs more than the Italian gas-fueled version.)
And this is no fly-by-night operation. The company’s been around for 15 years. You’ve likely seen pictures of their 3-wheeled cars.
So why am I interested now you may well ask?
Green expectations
The green initiatives pushed by the Obama Administration are creating the perfect opening for ZAP. In fact, the government has announced it intends to spend $300 million specifically on energy-efficient federal vehicles.
The U.S. military placed a trial order for the company’s Zaptruck XL back in June and in September, they reordered more vehicles and 220-volt charging stations.
In August, the FAA issued a contract for seven of their trucks. It’s not a huge amount, but it’s a foot in the door.
ZAP is also hoping to carve out a slice of the $2.4 billion outlay in the stimulus designated for the production of next generation plug-in hybrid electric vehicles and its battery components.
The company is ramping up production with the increased government – and corporate – interest in 100% electric vehicles.
Global ambitions
In September, ZAP announced French technology executive Georges Penalver has been brought in to chair its advisory board. The company formed the board of experts to help its recent expansion into the Asian and European markets.
Another new notable board member is veteran Wall Street financial wiz, William A. Shea, Jr.
That’s some high-powered expertise.
And with its price to sales ratio under 5, ZAP’s stock is fairly valued.
I recommend you pick up shares of ZAP (OTC:ZAAP) at or under $0.50 per share.
Our third pick is slightly higher-priced…
Top Penny Stock #3: Kerex Biopharmaceuticals, Inc. (NASDAQ:KERX)
Share price as of 10/07/2009: $2.19
Market Cap as of 10/07/2009: $104.77 million
http://www.keryx.com
Kerex Biopharmaceuticals develops and markets treatments for renal disease and cancer.
Two of the company’s drugs are about to begin Phase III trials…
Zenerex
Zenerex is an oral treatment that’s iron-based. It operates by binding phosphate and forming non-absorbable complexes.
A Phase III trial is pending for the treatment of hyperphosphatemia. This condition occurs in patients with end-stage renal disease on dialysis and is typically associated with other related conditions as well as the progression of renal failure.
In the U.S. alone, there are about 485, 000 people with end-stage renal disease and the number is expected to climb by 60% in the next 10 years.
Perifosine (KRX-0401)
Perifosine is also an oral treatment. It fights cancer by inhibiting signaling pathways that induce cell growth.
A Phase II trial has begun for Leukemia and Lymphoma and a Phase III trial is in the works under a Special Protocol Assessment from the FDA for the treatment of patients with multiple myeloma.
This company could be gold for investors that get in now.
I recommend you buy shares of Biopharma: Kerex Biopharmaceuticals, Inc. (NASDAQ:KERX) under $2.80.
No comments:
Post a Comment